These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24510534)

  • 21. C-learning: A new classification framework to estimate optimal dynamic treatment regimes.
    Zhang B; Zhang M
    Biometrics; 2018 Sep; 74(3):891-899. PubMed ID: 29228509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doubly robust estimation of optimal dynamic treatment regimes with multicategory treatments and survival outcomes.
    Zhang Z; Yi D; Fan Y
    Stat Med; 2022 Oct; 41(24):4903-4923. PubMed ID: 35948279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response in acute myeloid leukemia.
    Estey E
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):113-7. PubMed ID: 18347562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.
    Pavlík T; Janoušová E; Pospíšil Z; Mužík J; Záčková D; Ráčil Z; Klamová H; Cetkovský P; Trněný M; Mayer J; Dušek L
    BMC Med Res Methodol; 2011 Oct; 11():140. PubMed ID: 21988861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic treatment regimes: practical design considerations.
    Lavori PW; Dawson R
    Clin Trials; 2004 Feb; 1(1):9-20. PubMed ID: 16281458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
    Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
    Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Kearney M; Stevens JW; Benedict A; Bharmal M
    Pharmacoeconomics; 2019 Dec; 37(12):1537-1551. PubMed ID: 31555968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database.
    Simoneau G; Moodie EEM; Azoulay L; Platt RW
    Am J Epidemiol; 2020 May; 189(5):461-469. PubMed ID: 31903490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
    Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
    Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.
    Shen J; Wang L; Taylor JMG
    Biometrics; 2017 Jun; 73(2):635-645. PubMed ID: 27893926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
    Huang J; Gui C; Zhang L; Che F; Wang C
    Cell Physiol Biochem; 2018; 49(4):1589-1599. PubMed ID: 30223267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pool adjacent violators algorithm-assisted learning with application on estimating optimal individualized treatment regimes.
    Chen B; Yuan A; Qin J
    Biometrics; 2022 Dec; 78(4):1475-1488. PubMed ID: 34181761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
    Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P
    Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving toward individualized target-based therapies in acute myeloid leukemia.
    Bazinet A; Kantarjian HM
    Ann Oncol; 2023 Feb; 34(2):141-151. PubMed ID: 36423744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
    Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inference for non-regular parameters in optimal dynamic treatment regimes.
    Chakraborty B; Murphy S; Strecher V
    Stat Methods Med Res; 2010 Jun; 19(3):317-43. PubMed ID: 19608604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.